Sanofi grapples with rejection of potential first-in-class orphan drug, faults third-party manufacturing
A snap review didn’t lead to a quick OK for Sanofi’s sutimlimab. A day after the FDA’s supposed decision date on the orphan drug, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
